Polymer particles
US-2017081450-A1 · Mar 23, 2017 · US
US9907880B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9907880-B2 |
| Application number | US-201615081648-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 25, 2016 |
| Priority date | Mar 26, 2015 |
| Publication date | Mar 6, 2018 |
| Grant date | Mar 6, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embolic particles are described comprising a treated polymer particle. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer. The treated polymer particles can have a first diameter that is smaller than a second diameter, wherein the second diameter is achieved when the treated polymer particle is subjected to a physiological condition. Methods of making and using these polymer particles are also described.
Opening claim text (preview).
We claim: 1. An embolic composition comprising: embolic particles including a reaction product of a prepolymer solution including at least one macromer and at least one monomer, wherein the at least one macromer is poly(ethylene glycol) diacrylamide, poly(ethylene glycol) diacrylate, poly(ethylene glycol) dimethacrylate, poly(ethylene glycol) dimethacrylamide, or a combination thereof, wherein the embolic particles include acidic groups that are treated with an acidic solution to form treated embolic particles, wherein the treated embolic particles have a first diameter and a second diameter, and wherein the second diameter is larger than the first diameter when the treated polymer particle is subjected to a physiological condition, and wherein the embolic particles are substantially spherical, and wherein the first diameter is between about 50 μm and about 1,500 μm. 2. The embolic composition of claim 1 , wherein the first diameter is between about 400 μm and about 1,500 μm. 3. The embolic composition of claim 2 , wherein the first diameter is smaller than a diameter of a microcatheter. 4. The embolic composition of claim 1 , wherein the second diameter is between about 80 μm and about 3,600 μm. 5. The embolic composition of claim 4 , wherein the second diameter is larger than a diameter of a microcatheter. 6. The embolic composition of claim 1 , wherein the at least one monomer includes ionic groups. 7. The embolic composition of claim 6 , wherein the monomer containing ionic groups is sodium acrylate. 8. The embolic composition of claim 6 , wherein the prepolymer solution further includes a biodegradable crosslinker having a structure: wherein each n is independently 1-20; wherein d, e, f, and g are each independently 1-20; or 9. The embolic composition of claim 1 , wherein the embolic particles further include a visualization agent having a structure: 10. The embolic composition of claim 1 , wherein the physiological condition is physiological pH. 11. A method of making polymer particles comprising: treating polymer particles formed by reacting a prepolymer solution including at least one macromer, an acrylic monomer, and an initiator in non-solvent to form treated polymer particles; wherein the treated polymer particle has a first diameter and a second diameter, wherein the second diameter is larger than the first diameter when the treated polymer particle is subjected to a physiological condition, wherein the at least one macromer is poly(ethylene glycol) diacrylamide, poly(ethylene glycol) diacrylate, poly(ethylene glycol) dimethacrylate, poly(ethylene glycol) dimethacrylamide, or a combination thereof, wherein the embolic particles are substantially spherical, and wherein the first diameter is between about 50 μm and about 1,500 μm. 12. The method of claim 11 , wherein the non-solvent is a mineral oil, hexane, or water. 13. The method of claim 11 , wherein the initiator is ammonium persulfate, tetramethylethylene diamine, or a combination thereof. 14. The method of claim 11 , wherein the first diameter is smaller than the diameter of a microcatheter. 15. The method of claim 11 , wherein the second diameter is between about 80 μm and about 3,600 μm. 16. The method of claim 15 , wherein the second diameter is larger than the diameter of the microcatheter. 17. The method of claim 11 , wherein the treating is acid treating and the monomer containing ionic groups is sodium acrylate or the treating is base treating and the monomer containing ionic groups includes amino groups.
obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)} · CPC title
Use of materials characterised by their function or physical properties · CPC title
for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title
Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide · CPC title
Homopolymers or copolymers of methacrylic acid esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.